Jorge López-Leal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jorge López-Leal has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- César Jesús Eras Lévano
Universidad Privada San Juan Bautista - Escuela de Posgrado
1 shared publication - Fernando Quevedo-Candela
Sector de Hemodinamia y Cardiología Intervencionista, Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ), Québec, Canadá; Université Laval, Québec, Canadá
1 shared publication - Hady Keita
Universidad de la Sierra Sur, Oaxaca 70800, Mexico
1 shared publication - Jesús I. Parra Prado
Escuela de Medicina, Universidad Autónoma de Chihuahua, Chihuahua 31125, Mexico
1 shared publication - Joaquín Fernández Álvarez
NeumoVigo I+i Research Group, Galicia Sur Health Research Institute (IIS Galicia Sur), SERGAS-UVIGO, 36312 Vigo, Spain
1 shared publication - Joshuan Barboza Meca
Vicerrectorado de Investigación, Universidad Señor de Sipán, Chiclayo 14001, Peru
1 shared publication
Latest Publications
- Open Access
- 4 March 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (5) , 765
Prognostic Models for Predicting Coronary Heart Disease Risk in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
Background: Individuals with type 2 diabetes mellitus (T2DM) are at markedly increased risk of developing coronary heart disease (CHD); however, the generalizability and transportability of existing prediction models remain uncertain. Objective: To identify and evaluate multivariable prognostic models developed to predict CHD in adults with T2DM. Methods: We conducted a PRISMA-guided systematic review and meta-analysis of multivariable prognostic models predicting CHD in T2DM populations. Model characteristics and performance metrics were extracted following the CHARMS and TRIPOD-SRMA frameworks, and pooled discrimination was estimated on the logit-transformed AUC scale using a random-effects model (REML, Hartung–Knapp adjustment). Between-study heterogeneity and 95% prediction intervals were quantified, while risk of bias and applicability were assessed using the PROBAST tool. Results: Thirteen studies encompassing clinical, imaging-based, and omics-augmented models met the inclusion criteria. The pooled AUC was 0.69 (95% CI: 0.66–0.71), with high heterogeneity (I2 = 97.4%; τ2 = 0.0979) and a wide 95% prediction interval (0.54–0.81). Classical regression-based models demonstrated modest discrimination, whereas machine learning, imaging, and proteomic approaches achieved higher AUC estimates but were frequently constrained by small sample sizes, internal-only validation, and poor calibration reporting. The analysis domain emerged as the principal source of bias in PROBAST evaluations, and applicability issues were most frequent in models requiring advanced imaging or molecular platforms. Conclusions: Prognostic models for CHD in T2DM demonstrate moderate-to-good discrimination but substantial heterogeneity and frequent miscalibration across studies. Their clinical utility depends on rigorous external validation and local recalibration, particularly when incorporating imaging or molecular predictors. Future research should prioritize standardized CHD outcomes, consistent calibration reporting, decision-analytic assessments, and the development of transportable multimodal prediction models across diverse populations.
- 4 March 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (5) , 765
Open AccessPrognostic Models for Predicting Coronary Heart Disease Risk in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
Background: Individuals with type 2 diabetes mellitus (T2DM) are at markedly increased risk of developing coronary heart disease (CHD); however, the generalizability and transportability of existing prediction models remain uncertain. Objective: To identify and evaluate multivariable prognostic models developed to predict CHD in adults with T2DM. Methods: We conducted a PRISMA-guided systematic review and meta-analysis of multivariable prognostic models predicting CHD in T2DM populations. Model characteristics and performance metrics were extracted following the CHARMS and TRIPOD-SRMA frameworks, and pooled discrimination was estimated on the logit-transformed AUC scale using a random-effects model (REML, Hartung–Knapp adjustment). Between-study heterogeneity and 95% prediction intervals were quantified, while risk of bias and applicability were assessed using the PROBAST tool. Results: Thirteen studies encompassing clinical, imaging-based, and omics-augmented models met the inclusion criteria. The pooled AUC was 0.69 (95% CI: 0.66–0.71), with high heterogeneity (I2 = 97.4%; τ2 = 0.0979) and a wide 95% prediction interval (0.54–0.81). Classical regression-based models demonstrated modest discrimination, whereas machine learning, imaging, and proteomic approaches achieved higher AUC estimates but were frequently constrained by small sample sizes, internal-only validation, and poor calibration reporting. The analysis domain emerged as the principal source of bias in PROBAST evaluations, and applicability issues were most frequent in models requiring advanced imaging or molecular platforms. Conclusions: Prognostic models for CHD in T2DM demonstrate moderate-to-good discrimination but substantial heterogeneity and frequent miscalibration across studies. Their clinical utility depends on rigorous external validation and local recalibration, particularly when incorporating imaging or molecular predictors. Future research should prioritize standardized CHD outcomes, consistent calibration reporting, decision-analytic assessments, and the development of transportable multimodal prediction models across diverse populations.
- Open Access
- 10 December 2025
- Published by Science Publishing Group in European Journal of Clinical and Biomedical Sciences
- Vol. 11 (5) , 73-77
Distribution of Dipper, Non-dipper, or Riser Phenotypes in Patients with Mild OSA Untreated with CPAP at UMAA No. 68 in Chihuahua, Mexico
"Obstructive sleep apnea (OSA) is associated with alterations in blood pressure (BP) regulation, influencing hypertension (HTN) control and increasing cardiovascular risk, with three nocturnal BP patterns described: a 10–20% decrease (“dipper”), a 0–10% decrease (“non-dipper”), or an increase during sleep (“riser”). This analytical cross-sectional observational study aimed to identify the distribution of dipper, non-dipper, and riser phenotypes in patients with untreated mild OSA evaluated at UMAA No. 68, Chihuahua. Patients with a diagnosis of mild OSA who were not receiving CPAP therapy were included, and data from 2021–2023 were obtained from the pulmonology service. Twenty-four–hour ambulatory blood pressure monitoring (ABPM) was performed, and SPSS v26 was used for statistical analysis. A total of 70 patients were analyzed (mean age 54.46 ± 15.9 years; 55.7% women), with hypertension documented in 31.4% of participants; overall, 82.9% exhibited a dipper phenotype and 17.1% a riser phenotype. The dipper phenotype predominated among patients with untreated mild OSA, while the riser phenotype was present in 17.1% of cases-approximately twice the prevalence reported in the general population-suggesting that nocturnal BP phenotype should be considered a relevant clinical feature in this population."
- 10 December 2025
- Published by Science Publishing Group in European Journal of Clinical and Biomedical Sciences
- Vol. 11 (5) , 73-77
Open AccessDistribution of Dipper, Non-dipper, or Riser Phenotypes in Patients with Mild OSA Untreated with CPAP at UMAA No. 68 in Chihuahua, Mexico
"Obstructive sleep apnea (OSA) is associated with alterations in blood pressure (BP) regulation, influencing hypertension (HTN) control and increasing cardiovascular risk, with three nocturnal BP patterns described: a 10–20% decrease (“dipper”), a 0–10% decrease (“non-dipper”), or an increase during sleep (“riser”). This analytical cross-sectional observational study aimed to identify the distribution of dipper, non-dipper, and riser phenotypes in patients with untreated mild OSA evaluated at UMAA No. 68, Chihuahua. Patients with a diagnosis of mild OSA who were not receiving CPAP therapy were included, and data from 2021–2023 were obtained from the pulmonology service. Twenty-four–hour ambulatory blood pressure monitoring (ABPM) was performed, and SPSS v26 was used for statistical analysis. A total of 70 patients were analyzed (mean age 54.46 ± 15.9 years; 55.7% women), with hypertension documented in 31.4% of participants; overall, 82.9% exhibited a dipper phenotype and 17.1% a riser phenotype. The dipper phenotype predominated among patients with untreated mild OSA, while the riser phenotype was present in 17.1% of cases-approximately twice the prevalence reported in the general population-suggesting that nocturnal BP phenotype should be considered a relevant clinical feature in this population."